logo
Plus   Neg
Share
Email

China Pharma Posts Wider Loss In FY19 - Quick Facts

China Pharma Holdings, Inc. (CPHI) reported a full year 2019 loss per common share of $0.48 compared to a loss of $0.25, previous year. Gross margin was 13.6% compared to 16.0%. Gross profit was $1.5 million, compared to $2.0 million, previous year.

Full year 2019 revenue decreased 11.4% to $11.0 million from $12.3 million, prior year. The company said this decrease in sales revenue was mainly due to the increased standards of drug tender procurement of GPO and the decreased "drug ratio".

For comments and feedback contact: editorial@rttnews.com

Business News

Editors Pick
FedEx is asking NFL team Washington Redskins to change its name for its racist connotations. The delivery services company, which is a major sponsor for the team, made the suggestion following increasing pressure from its investors amid the ongoing protests against racial injustice and inequality that arose from the killing of African-American George Floyd. Avalon Furniture is recalling about 9,500 units of Cottage Town Bedroom Furniture collection sold through Rooms To Go due to violation of federal lead paint ban, the U.S. Consumer Product Safety Commission said in a statement. According to the agency, the base coat paint used on pieces within the furniture collection contains levels of lead that exceed the federal lead paint standard. Sanofi and Regeneron Pharmaceuticals, Inc. announced that the U.S. Phase 3 trial of arthritis drug Kevzara (sarilumab) 400 mg in COVID-19 patients requiring mechanical ventilation did not meet its primary and key secondary endpoints. In the trial, Kevzara was added to best supportive care compared to best supportive care alone (placebo). The companies have stopped the U.S. trial.
RELATED NEWS
Follow RTT